Filter by:
Topic
Resource Type
Audience
Display Only
Showing 35 Results
How the Myth of Average Persists in Health Benefits
People are different and their health needs vary. Though differences among patients are common, these differences aren’t always considered in treatment and coverage decisions.
The Myth of Average: Why Individual Patient Differences Matter
NPC's "The Myth of Average" explores how patients, health care providers, insurers, and other decision-makers can better consider individual patient differences when navigating the complexities of…
NPC Patient-Reported Measures Research Featured at AMCP Nexus 2020
A panel at the Academy of Managed Care Pharmacy Nexus 2020 explored the tension between patient-reported measures funding and innovation and highlighted published research by NPC and Discern Health.
Supporting Value-Based Purchasing Through Changes in Medicaid Best Price
In a recent column for PharmaBoardroom, Michael Ciarametaro, vice president for research at the National Pharmaceutical Council, elaborated on the ways in which MBP presents a barrier to creative…
A Path of Her Own: Salama Freed, 2020-22 NPC/Duke-Margolis Health Policy Fellow
Salama Freed, PhD, has always wanted to learn about the inner-world of health policy – who shapes it, what drives it and how it gets done. She believes that her path to this experience is through the…
Do Patient Preferences Align with Value Frameworks? A Discrete-Choice Experiment of Patients with Breast Cancer
The study assessed patient preferences for aspects of breast-cancer treatments to evaluate the usual assumptions in scoring rubrics for value frameworks.
Are Value-based Arrangements the Answer We’ve Been Waiting for?
This NPC study explored the use of value-based arrangements as a mechanism for cost containment in the United States, noting the strengths and limitations of these tools.
U.S. Care Pathways: Continued Focus on Oncology and Outstanding Challenges
A peer-reviewed study assessed changes in development, implementation, and evaluation of care pathways, and reviewed the latest evidence on integration of pathways with value-based care initiatives…
Value-Based Agreements May Be More Prevalent Than Assumed
As the US health care system continues to transition from volume to value, NPC/Duke-Margolis research shows that value-based agreements between payers and biopharmaceutical manufacturers may be more…
Value-Based Agreements May Be More Prevalent Than Assumed
Research published in AJMC shows that value-based agreements (VBAs) between U.S. payers and biopharmaceutical manufacturers may be more prevalent than originally thought.
Bringing Patient-Centeredness to Quality Measurement in Health Care
Quality measures can help payers to reward better care, providers to take action to improve care, and patients to make informed decisions about where to seek care. Often, quality measures are focused…
NPC in Specialty Pharmacy Times: Health Care Economic Information and Its Impact on Value-Based Contracts
In his latest column in Specialty Pharmacy Times, NPC President and Chief Executive Officer Dan Leonard explains how expanding HCEI for sophisticated audiences like payers and population health…
Social Determinants of Health May Be Key to Value-based Care
There is growing recognition that improving access to care and patient health, including access to medications, requires focus on social, economic and environmental factors. At its upcoming…
Evaluation of Person-level Heterogeneity of Treatment Effects in Published Multiperson N-of-1 Studies: Systematic Review and Reanalysis
To understand when and how individual treatment effects are examined, conducted and reported, this study evaluated existing multiperson N-of-1 studies, which can identify whether an intervention is…
Regulatory Barriers Impair Alignment of Biopharmaceutical Price and Value
This white paper highlights the challenges biopharmaceutical manufacturers and payers face when developing value-based contracts.
NPC in Chain Drug Review: Pharmacy Outlook 2018
NPC President Dan Leonard explores value- and outcomes-based contracts, innovative benefit design, value assessment frameworks and more in his latest commentary for Chain Drug Review.
Opportunities and Challenges With Value-Based Contracting
In his commentary for the American Journal of Pharmacy Benefits, NPC President Dan Leonard explores the challenges and opportunities in implementing value-based contracts.
Learn More About Oncology Clinical Pathways in Webinar from Turning the Tide Against Cancer
Ideally, clinical pathways can be a useful tool to help clinicians make sense of quickly evolving science, ensure patients receive the right care at the right time, help standardize care and limit…
AMCP Partnership Forum on Value in Oncology Proceedings Published in JMCP
The Journal of Managed Care & Specialty Pharmacy this week published the proceedings from the Academy of Managed Care Pharmacy partnership forum, “Driving Value and Outcomes in Oncology,” which…